Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas, 9th edition

Published:February 13, 2020DOI:https://doi.org/10.1016/j.diabres.2020.108072

      Abstract

      Aims

      Diabetes and its complications have a significant economic impact on individuals and their families, health systems and national economies.

      Methods

      The direct health expenditure of diabetes was calculated relying on the following inputs: diagnosed and undiagnosed diabetes prevalence estimates, United Nations population estimates, World Health Organization health expenditure per capita and ratios of health expenditure for people with diabetes compared to people without diabetes.

      Results

      The estimated global direct health expenditure on diabetes in 2019 is USD 760 billion and is expected to grow to a projected USD 825 billion by 2030 and USD 845 billion by 2045. There is a wide variation in annual health expenditures on diabetes. The United States of America has the highest estimated expenditure with USD 294.6 billion, followed by China and Brazil, with USD 109.0 billion and USD 52.3 billion, respectively. The age group with the largest annual diabetes-related health expenditure is 60–69 years with USD 177.7 billion, followed by 50–59 years, and 70–79 years with USD 173.0 billion and USD 171.5 billion, respectively. Slightly higher diabetes-related health expenditure is seen in women than in men (USD 382.6 billion vs. USD 377.6 billion, respectively). The same difference is expected to be present in 2030 and 2045.

      Conclusions

      There were large disparities between high-, middle- and low-income countries with total health expenditures in high-income countries being over 300 times those in low-income countries. The ratio for annual direct health expenditure per person between these groups of countries is more than 38-fold.

      Keywords

      To read this article in full you will need to make a payment

      References

        • Williams R.
        The costs of diabetes.
        in: International Diabetes Federation. IDF Diabetes Atlas. 1st ed. International Diabetes Federation, Brussels, Belgium2000: 225-231
        • Williams R.
        The Economic Impact of Diabetes.
        in: International Diabetes Federation. IDF Diabetes Atlas. 2nd ed. International Diabetes Federation, Brussels, Belgium2003: 175-192
        • Brown J.B.
        • et al.
        The Economic Impacts of Diabetes.
        in: International Diabetes Federation. IDF Diabetes Atlas. 3rd ed. International Diabetes Federation, Brussels, Belgium2006: 237-265
        • International Diabetes Federation
        IDF Diabetes Atlas. 9th ed. International Diabetes Federation, Brussels, Belgium2019
        • Williams R.
        • Van Gaal L.
        Lucioni C (on behalf of the CODE-2 Advisory Board). Assessing the impact of complications on the costs of Type 2 diabetes.
        Diabetologia. 2002; 45: S13-S17
        • American Diabetes Association
        Economic Costs of Diabetes in the U.S. in 2017.
        Diabetes Care. 2018; 41: 917-928
      1. Spencer Bonilla, G., Rodriguez-Gutierrez, R., & Montori, V. M. (2016). What We Don’t Talk About When We Talk About Preventing Type 2 Diabetes—Addressing Socioeconomic Disadvantage. JAMA Internal Medicine, 2016; 176(8): E1-E2.

        • Dhatariya K.K.
        • Parsekar K.
        • Skedgel C.
        • Datta V.
        • Hill P.
        • Fordham R.
        The cost of treating diabetic ketoacidosis in an adolescent population in the UK: a national survey of hospital resource use.
        Diabet Med. 2019; 36: 982-987https://doi.org/10.1111/dme.2019.36.issue-810.1111/dme.13893
        • Coresh J.
        • Astor B.C.
        • Greene T.
        • Eknoyan G.
        • Levey A.S.
        Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third national health and nutrition examination survey.
        Am J Kidney Dis. 2003 Jan; 41: 1-12
        • Basit A.
        • Nawaz A.
        Preventing diabetes-related amputations in a developing country–steps in the right direction.
        Diabetes Voice. 2013; 58: 36-39
        • Li R.
        • Bilik D.
        • Brown M.B.
        • Zhang P.
        • Ettner S.L.
        • Ackermann R.T.
        • et al.
        Medical costs associated with type 2 diabetes complications and comorbidities.
        Am J Manag Care. 2013 May; 19: 421-430
        • Kähm K.
        • Laxy M.
        • Schneider U.
        • Rogowski W.H.
        • Lhachimi S.K.
        • Holle R.
        Health care costs associated with incident complications in patients with type 2 diabetes in Germany.
        Diab Care. 2018; 41: 971-978
        • Zhuo X.
        • Zhang P.
        • Hoerger T.J.
        Lifetime direct medical costs of treating type 2 diabetes and diabetic complications.
        Am J Prev Med. 2013 Sep; 45: 253-261
        • Marcellusi A.
        • Viti R.
        • Sciattella P.
        • Aimaretti G.
        • De Cosmo S.
        • Provenzano V.
        • et al.
        Economic aspects in the management of diabetes in Italy.
        BMJ Open Diabetes Res Care. 2016 Oct; 4e000197
        • Ezzati M.
        • Lopez A.D.
        • Rodgers A.
        • Vander Hoorn S.
        • Murray C.J.
        Selected major risk factors and global and regional burden of disease.
        The Lancet. 2002; 360: 1347-1360
      2. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th ed. Diabetes Research and Clinical Practice 2019;157:107843.

      3. World Health Organization. World Health Organization. Global Health Expenditure database. 2019. Available from: https://apps.who.int/nha/database.

        • Bommer C.
        • Heesemann E.
        • Sagalova V.
        • Manne-Goehler J.
        • Atun R.
        • Bärnighausen T.
        • et al.
        The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study.
        Lancet Diabetes Endocrinol. 2017; 5: 423-430https://doi.org/10.1016/S2213-8587(17)30097-9
        • Bommer C.
        • Sagalova V.
        • Heesemann E.
        • Manne-Goehler J.
        • Atun R.
        • Bärnighausen T.
        • et al.
        Global economic burden of diabetes in adults: projections from 2015 to 2030.
        Diabetes Care. 2018; 41: 963-970https://doi.org/10.2337/dc17-1962
        • Afroz A.
        • Alam K.
        • Ali A.
        • Karim A.
        • Alramadan M.J.
        • Habib S.H.
        • et al.
        Type 2 diabetes mellitus in Bangladesh: a prevalence based cost-of-illness study.
        BMC Health Serv Res. 2019; 19: 601https://doi.org/10.1186/s12913-019-4440-3
        • Bermudez-Tamayo C.
        • Besançon S.
        • Johri M.
        • Assa S.
        • Brown J.B.
        • Ramaiya K.
        Direct and indirect costs of diabetes mellitus in Mali: A case-control study.
        PLoS One. 2017; 12https://doi.org/10.1371/journal.pone.0176128
        • Alouki K.
        • Delisle H.
        • Besançon S.
        Analysis of direct medical costs of type 2 diabetes in Mali.
        Rev Epidemiol Sante Publique. 2017; 65: 41-51https://doi.org/10.1016/j.respe.2016.06.334
        • Khowaja L.A.
        • Khuwaja A.K.
        • Cosgrove P.
        Cost of diabetes care in out-patient clinics of Karachi, Pakistan.
        BMC Health Serv Res. 2007; https://doi.org/10.1186/1472-6963-7-189
        • Lebbe S.M.A.
        • Rinosha K.F.
        Economic Cost of Diabetes in Ampara District in Sri Lanka.
        J. Politics Law. 2018; 11: 146-152https://doi.org/10.5539/jpl.v11n4p146
        • Elrayah-Eliadarous H.
        • Yassin K.
        • Eltom M.
        • Abdelrahman S.
        • Wahlström R.
        • Ostenson C.G.
        Direct costs for care and glycaemic control in patients with type 2 diabetes in Sudan.
        Exp Clin Endocrinol Diabetes. 2010; 118: 220-225https://doi.org/10.1055/s-0029-1246216
        • Brown J.B.
        • Ramaiya K.
        • Besançon S.
        • Rheeder P.
        • Tassou C.M.
        • Mbanya J.C.
        • et al.
        Use of medical services and medicines attributable to diabetes in Sub-Saharan Africa.
        PLoS One. 2014; 9: e106716https://doi.org/10.1371/journal.pone.0106716
        • Esteghamati A.
        • Khalilzadeh O.
        • Anvari M.
        • Meysamie A.
        • Abbasi M.
        • Forouzanfar M.
        • et al.
        The economic costs of diabetes: a population-based study in Tehran, Iran.
        Diabetologia. 2009; 52: 1520-1527https://doi.org/10.1007/s00125-009-1398-4
        • Basit A.
        • Fawwad A.
        • Baqa K.
        Pakistan and diabetes-A country on the edge.
        Diabetes Res Clin Pract. 2019; 147: 166-168https://doi.org/10.1016/j.diabres.2018.11.001
        • Cylus J.
        • Thomson S.
        • Evetovits T.
        Catastrophic health spending in Europe: equity and policy implications of different calculation methods.
        Bull World Health Organ. 2018; 96: 599-609https://doi.org/10.2471/BLT.18.209031
        • Cavanagh P.
        • Attinger C.
        • Abbas Z.
        • Bal A.
        • Rojas N.
        • Xu Z.R.
        Cost of treating diabetic foot ulcers in five different countries.
        Diabetes Metab Res Rev. 2012; 28: 107-111https://doi.org/10.1002/dmrr.2245
        • Jo C.
        Cost-of-illness studies: concepts, scopes, and methods.
        Clin Mol Hepatol. 2014; 20: 327-337https://doi.org/10.3350/cmh.2014.20.4.327